Floatz logo

Dfn-15

Sarcoma

National Cancer Institute (NCI)Phase 2Dormant
B
58/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
73/ 100

Competitive context

110 Active assets in the Sarcoma cohort.

Asset / SponsorPhaseRating
ETOPOSIDE
National Cancer Institute (NCI)
Phase 2BB
Cyclophosphamide
Essen Biotech
Phase 2BB
Ifosfamide
City of Hope Medical Center
Phase 3BB
Inno-206
City of Hope Medical Center
Phase 3BB
CIS-DIAMMINEDICHLOROPLATINUM II
Roswell Park Cancer Institute
Phase 2BB

View all 50 →

Same molecule, other indications

Dfn-15 is also rated in:

osteoarthritis, hipDormant
BB
Indicative ·
71 / 100
View asset →
osteoarthritis, kneeDormant
BB
Indicative ·
69 / 100
View asset →
ArthritisDormant
BB
Indicative ·
68 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →